×
QQQ   292.17 (+1.17%)
AAPL   145.16 (+1.57%)
MSFT   267.37 (+0.44%)
META   169.41 (-0.21%)
GOOGL   2,323.12 (+1.38%)
AMZN   114.70 (+0.32%)
TSLA   717.39 (+3.19%)
NVDA   155.95 (+3.07%)
NIO   22.93 (+10.08%)
BABA   124.32 (+4.37%)
AMD   78.57 (+4.27%)
MU   58.31 (+1.64%)
CGC   2.69 (+1.51%)
T   21.05 (-0.19%)
GE   62.68 (+1.80%)
F   11.44 (+3.44%)
DIS   96.93 (+0.88%)
AMC   12.79 (+1.75%)
PFE   53.22 (+0.89%)
PYPL   73.72 (+0.66%)
NFLX   186.64 (+1.40%)
QQQ   292.17 (+1.17%)
AAPL   145.16 (+1.57%)
MSFT   267.37 (+0.44%)
META   169.41 (-0.21%)
GOOGL   2,323.12 (+1.38%)
AMZN   114.70 (+0.32%)
TSLA   717.39 (+3.19%)
NVDA   155.95 (+3.07%)
NIO   22.93 (+10.08%)
BABA   124.32 (+4.37%)
AMD   78.57 (+4.27%)
MU   58.31 (+1.64%)
CGC   2.69 (+1.51%)
T   21.05 (-0.19%)
GE   62.68 (+1.80%)
F   11.44 (+3.44%)
DIS   96.93 (+0.88%)
AMC   12.79 (+1.75%)
PFE   53.22 (+0.89%)
PYPL   73.72 (+0.66%)
NFLX   186.64 (+1.40%)
QQQ   292.17 (+1.17%)
AAPL   145.16 (+1.57%)
MSFT   267.37 (+0.44%)
META   169.41 (-0.21%)
GOOGL   2,323.12 (+1.38%)
AMZN   114.70 (+0.32%)
TSLA   717.39 (+3.19%)
NVDA   155.95 (+3.07%)
NIO   22.93 (+10.08%)
BABA   124.32 (+4.37%)
AMD   78.57 (+4.27%)
MU   58.31 (+1.64%)
CGC   2.69 (+1.51%)
T   21.05 (-0.19%)
GE   62.68 (+1.80%)
F   11.44 (+3.44%)
DIS   96.93 (+0.88%)
AMC   12.79 (+1.75%)
PFE   53.22 (+0.89%)
PYPL   73.72 (+0.66%)
NFLX   186.64 (+1.40%)
QQQ   292.17 (+1.17%)
AAPL   145.16 (+1.57%)
MSFT   267.37 (+0.44%)
META   169.41 (-0.21%)
GOOGL   2,323.12 (+1.38%)
AMZN   114.70 (+0.32%)
TSLA   717.39 (+3.19%)
NVDA   155.95 (+3.07%)
NIO   22.93 (+10.08%)
BABA   124.32 (+4.37%)
AMD   78.57 (+4.27%)
MU   58.31 (+1.64%)
CGC   2.69 (+1.51%)
T   21.05 (-0.19%)
GE   62.68 (+1.80%)
F   11.44 (+3.44%)
DIS   96.93 (+0.88%)
AMC   12.79 (+1.75%)
PFE   53.22 (+0.89%)
PYPL   73.72 (+0.66%)
NFLX   186.64 (+1.40%)
NASDAQ:IART

Integra LifeSciences Stock Forecast, Price & News

$54.63
+0.27 (+0.50%)
(As of 07/7/2022 09:53 AM ET)
Add
Compare
Today's Range
$54.36
$54.98
50-Day Range
$53.86
$62.64
52-Week Range
$53.22
$76.70
Volume
1,686 shs
Average Volume
504,381 shs
Market Capitalization
$4.54 billion
P/E Ratio
29.69
Dividend Yield
N/A
Price Target
$71.83

Integra LifeSciences MarketRank™ Forecast

Analyst Rating
Hold
2.14 Rating Score
Upside/​Downside
32.1% Upside
$71.83 Price Target
Short Interest
Bearish
5.48% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.50
Upright™ Environmental Score
News Sentiment
0.00mentions of Integra LifeSciences in the last 14 days
Based on 2 Articles This Week
Insider Trading
Selling Shares
$65,300 Sold Last Quarter
Proj. Earnings Growth
9.97%
From $3.31 to $3.64 Per Share

Overall MarketRank

MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.

2.32 out of 5 stars

Medical Sector

85th out of 1,433 stocks

Surgical & Medical Instruments Industry

13th out of 137 stocks

30 days | 90 days | 365 days | Advanced Chart

Receive IART Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Integra LifeSciences and its competitors with MarketBeat's FREE daily newsletter.

Integra LifeSciences logo

About Integra LifeSciences (NASDAQ:IART) Stock

Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, and general surgery. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as asset management software and support, and after-market services. It also sells approximately 40,000 instrument patterns, and surgical and lighting products to hospitals and surgery centers, as well as dental, podiatry, and veterinary offices. In addition, the company provides regenerative technology products for the treatment of acute and chronic wounds; and surgical tissue repair products for hernia repair, peripheral nerve repair and protection, and tendon repair. Further, it offers skin and wound repair, plastics and surgical reconstruction products, bone grafts, and nerve and tendon repair products. The company offers its products directly through various sales forces and other distribution channels to the hospitals, integrated health networks, group purchasing organizations, clinicians, surgery centers, and health care providers in the United States, Europe, Asia Pacific, and internationally. Integra LifeSciences Holdings Corporation was incorporated in 1989 and is headquartered in Princeton, New Jersey.

IART Stock News Headlines

Integra LifeSciences Holdings Corporation
Integra LifeSciences Tops Q1 EPS by 6c
See More Headlines

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
Health Care Equipment
Sector
Medical
Current Symbol
NASDAQ:IART
CUSIP
45798520
Employees
3,800
Year Founded
N/A

Company Calendar

Last Earnings
4/27/2022
Today
7/07/2022
Next Earnings (Confirmed)
7/27/2022
Fiscal Year End
12/31/2022

Price Target and Rating

Average Stock Price Forecast
$71.83
High Stock Price Forecast
$87.00
Low Stock Price Forecast
$65.00
Forecasted Upside/Downside
+31.5%
Consensus Rating
Hold
Rating Score (0-4)
2.14285714285714
Research Coverage
7 Analysts

Profitability

Net Income
$169.07 million
Pretax Margin
11.98%

Debt

Sales & Book Value

Annual Sales
$1.54 billion
Cash Flow
$4.73 per share
Book Value
$19.89 per share

Miscellaneous

Free Float
79,643,000
Market Cap
$4.54 billion
Optionable
Optionable
Beta
1.13

Social Links















Integra LifeSciences Frequently Asked Questions

Should I buy or sell Integra LifeSciences stock right now?

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Integra LifeSciences in the last year. There are currently 1 sell rating, 4 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" Integra LifeSciences stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in IART, but not buy additional shares or sell existing shares.
View analyst ratings for Integra LifeSciences
or view top-rated stocks.

What is Integra LifeSciences' stock price forecast for 2022?

7 brokerages have issued 1 year target prices for Integra LifeSciences' stock. Their IART stock forecasts range from $65.00 to $87.00. On average, they anticipate Integra LifeSciences' share price to reach $71.83 in the next twelve months. This suggests a possible upside of 30.9% from the stock's current price.
View analysts' price targets for Integra LifeSciences
or view top-rated stocks among Wall Street analysts.

How has Integra LifeSciences' stock price performed in 2022?

Integra LifeSciences' stock was trading at $66.99 at the beginning of 2022. Since then, IART stock has decreased by 18.1% and is now trading at $54.88.
View the best growth stocks for 2022 here
.

When is Integra LifeSciences' next earnings date?

Integra LifeSciences is scheduled to release its next quarterly earnings announcement on Wednesday, July 27th 2022.
View our earnings forecast for Integra LifeSciences
.

How can I listen to Integra LifeSciences' earnings call?

Integra LifeSciences will be holding an earnings conference call on Wednesday, July 27th at 8:30 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at 888-203-1112 with passcode "2688312".

How were Integra LifeSciences' earnings last quarter?

Integra LifeSciences Holdings Co. (NASDAQ:IART) announced its earnings results on Wednesday, April, 27th. The life sciences company reported $0.74 earnings per share for the quarter, beating the consensus estimate of $0.68 by $0.06. The life sciences company earned $376.60 million during the quarter, compared to analysts' expectations of $362.19 million. Integra LifeSciences had a trailing twelve-month return on equity of 16.88% and a net margin of 10.04%. The company's quarterly revenue was up 4.6% on a year-over-year basis. During the same quarter last year, the business posted $0.69 EPS.
View Integra LifeSciences' earnings history
.

When did Integra LifeSciences' stock split? How did Integra LifeSciences' stock split work?

Shares of Integra LifeSciences split on Tuesday, January 3rd 2017. The 2-1 split was announced on Thursday, December 22nd 2016. The newly issued shares were payable to shareholders after the market closes on Wednesday, December 21st 2016. An investor that had 100 shares of Integra LifeSciences stock prior to the split would have 200 shares after the split.

What guidance has Integra LifeSciences issued on next quarter's earnings?

Integra LifeSciences updated its FY22 earnings guidance on Wednesday, April, 27th. The company provided earnings per share guidance of $3.27-3.35 for the period, compared to the consensus estimate of $3.31. The company issued revenue guidance of $1.58-1.60 billion, compared to the consensus revenue estimate of $1.59 billion.

Who are Integra LifeSciences' key executives?

Integra LifeSciences' management team includes the following people:

What is Peter J. Arduini's approval rating as Integra LifeSciences' CEO?

173 employees have rated Integra LifeSciences CEO Peter J. Arduini on Glassdoor.com. Peter J. Arduini has an approval rating of 74% among Integra LifeSciences' employees.

What other stocks do shareholders of Integra LifeSciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Integra LifeSciences investors own include Boeing (BA), NVIDIA (NVDA), AbbVie (ABBV), Adobe (ADBE), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Intel (INTC), Marvell Technology (MRVL), Alexion Pharmaceuticals (ALXN) and Abbott Laboratories (ABT).

What is Integra LifeSciences' stock symbol?

Integra LifeSciences trades on the NASDAQ under the ticker symbol "IART."

How do I buy shares of Integra LifeSciences?

Shares of IART can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Integra LifeSciences' stock price today?

One share of IART stock can currently be purchased for approximately $54.88.

How much money does Integra LifeSciences make?

Integra LifeSciences (NASDAQ:IART) has a market capitalization of $4.56 billion and generates $1.54 billion in revenue each year. The life sciences company earns $169.07 million in net income (profit) each year or $1.84 on an earnings per share basis.

How many employees does Integra LifeSciences have?

Integra LifeSciences employs 3,800 workers across the globe.

How can I contact Integra LifeSciences?

Integra LifeSciences' mailing address is 311 ENTERPRISE DRIVE, PLAINSBORO NJ, 08536. The official website for Integra LifeSciences is www.integralife.com. The life sciences company can be reached via phone at (609) 275-0500, via email at ir@integralife.com, or via fax at 609-750-4277.

This page (NASDAQ:IART) was last updated on 7/7/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.